Related Experiment Video

Updated: Aug 19, 2026

Three-Dimensional (3D) Tumor Spheroid Invasion Assay
12:19

Three-Dimensional (3D) Tumor Spheroid Invasion Assay

Published on: May 1, 2015

Epidermal growth factor receptor--mediated stat3 signaling blocks apoptosis in head and neck cancer

J Rubin Grandis1, Q Zeng, S D Drenning

  • 1University of Pittsburgh School of Medicine, Department of Otolaryngology, Pennsylvania, USA. jgrandis+@pitt.edu

The Laryngoscope
|May 12, 2000
PubMed
Abstract

Insights

Epidermal growth factor receptor (EGFR) signaling drives head and neck cancer growth by activating Stat3. Inhibiting Stat3 through gene therapy reduces tumor growth and promotes cancer cell death, offering a potential therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Epidermal growth factor receptor (EGFR) upregulation is crucial for uncontrolled growth in various cancers, including head and neck squamous cell carcinoma (SCCHN).
  • EGFR signaling in SCCHN cells triggers persistent activation of Signal Transducer and Activator of Transcription (STAT) proteins, particularly Stat3.

Purpose of the Study:

  • To investigate the in vivo association between EGFR stimulation and constitutive Stat3 activation in SCCHN.
  • To examine the effects of Stat3 downmodulation on SCCHN cell proliferation and apoptosis in vitro.

Main Methods:

  • Analysis of SCCHN tumor xenografts using electrophoretic mobility shift assay.
  • Transfection of SCCHN cells with dominant-negative Stat3 or Stat3 antisense plasmids.
  • Assessment of cell growth and apoptosis via vital dye exclusion and flow cytometry.

Main Results:

  • Liposome-mediated in vivo gene therapy using an EGFR antisense plasmid effectively suppressed Stat3 activation in a head and neck xenograft model.
  • Downmodulation of Stat3, achieved through dominant-negative or antisense methods, resulted in inhibited tumor cell growth.
  • Stat3 inhibition stimulated apoptosis in SCCHN cells.

Conclusions:

  • Constitutively activated Stat3 is demonstrably linked to EGFR signaling in SCCHN.
  • This EGFR-Stat3 axis contributes to the loss of growth control in SCCHN through an anti-apoptotic mechanism.
  • Targeting Stat3 represents a promising therapeutic avenue for SCCHN.

More Related Videos

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death09:18

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death

Published on: December 27, 2016

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...